Third Rock funds disclose Maze Therapeutics stakes
Maze Therapeutics, Inc. received an updated Schedule 13G/A from several affiliated Third Rock Ventures funds reporting their ownership of the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. received an updated Schedule 13G/A from several affiliated Third Rock Ventures funds reporting their ownership of the company’s common stock. Third Rock Ventures IV, L.P. directly holds 4,473,958 shares of common stock, which represents approximately 9.3% of Maze’s outstanding shares based on 48,119,440 shares outstanding as of November 3, 2025. Third Rock Ventures V, L.P. directly holds 950,800 shares, representing about 2.0% of the outstanding stock on the same basis.
Related general partner entities (Third Rock Ventures GP IV, L.P., TRV GP IV, LLC, Third Rock Ventures GP V, L.P., and TRV GP V, LLC) may be deemed to share voting and dispositive power over these shares, but they report no sole voting or dispositive power. The reporting persons expressly disclaim the existence of a “group” for regulatory purposes.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Third Rock Ventures report owning in Maze Therapeutics (MAZE)?
What percentage of Maze Therapeutics’ stock is held by Third Rock funds?
Which Third Rock entities are included in this Maze Therapeutics Schedule 13G/A?
How was the ownership percentage in Maze Therapeutics (MAZE) calculated?
Do the Third Rock entities acknowledge forming a group in this MAZE ownership filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.